Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for…
Art, Mode of action & Overview
Explore the main themes, entities and connections around Lapatinib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
cancer breast combination her2 patients kinase drug used tykerb ditosylate egfr clinical capecitabine chemotherapy tyrosine receptor therapy her2-positive treatment names
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Lapatinib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Lapatinib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Lapatinib | ATC code | L01EH01 (WHO) | 1.00 | infobox |
| Lapatinib | Bioavailability | Variable, increased with food | 1.00 | infobox |
| Lapatinib | CAS Number | 231277-92-2 N | 1.00 | infobox |
| Lapatinib | CAS Number | as salt: 388082-78-8 N | 1.00 | infobox |
| Lapatinib | ChEBI | CHEBI:49603 Y | 1.00 | infobox |
| Lapatinib | ChEMBL | ChEMBL554 Y | 1.00 | infobox |
| Lapatinib | ChEMBL | as salt: ChEMBL1201179 Y | 1.00 | infobox |
| Lapatinib | ChemSpider | 181006 Y | 1.00 | infobox |
| Lapatinib | ChemSpider | as salt: 9731817 Y | 1.00 | infobox |
| Lapatinib | CompTox Dashboard (EPA) | DTXSID7046675 | 1.00 | infobox |
| Lapatinib | DrugBank | DB01259 Y | 1.00 | infobox |
| Lapatinib | DrugBank | as salt: DBSALT001785 Y | 1.00 | infobox |
| Lapatinib | Elimination half-life | 24 hours (repeated dosing), 14.2 hours (single dose) | 1.00 | infobox |
| Lapatinib | Excretion | Mostly Feces | 1.00 | infobox |
| Lapatinib | Formula | C29H26ClFN4O4S | 1.00 | infobox |
| Lapatinib | IUPHAR/BPS | 5692 | 1.00 | infobox |
| Lapatinib | KEGG | D08108 N | 1.00 | infobox |
| Lapatinib | KEGG | as salt: D04024 N | 1.00 | infobox |
| Lapatinib | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Lapatinib | Legal status | CA: ℞-only | 1.00 | infobox |
| Lapatinib | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Lapatinib | Legal status | US: ℞-only | 1.00 | infobox |
| Lapatinib | Legal status | EU: Rx-only | 1.00 | infobox |
| Lapatinib | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Lapatinib | License data | US DailyMed: Lapatinib | 1.00 | infobox |
| Lapatinib | MedlinePlus | a607055 | 1.00 | infobox |
| Lapatinib | Metabolism | Liver, mostly CYP3A-mediated (minor 2C19 and 2C8 involvement) | 1.00 | infobox |
| Lapatinib | Molar mass | 581.06 g·mol−1 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.